ReviewFrontiers in endocrinology2019
Extragonadal FSHR Expression and Function-Is It Real?
Review in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Polymorphisms in FSHR modulating susceptibility to polycystic ovary syndrome: an updated meta-analysis.Journal of ovarian research · 2023Pooled it
- Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging.Journal of clinical medicine · 2026Review
- The therapeutic potential of pirfenidone in alleviating fibrosis and restoring ovarian function in a novel ovarian endometriosis mouse model.Journal of translational medicine · 2026Article
- Targeted destruction of follicle stimulating hormone receptor-positive cancer cells in vitro and in vivo by a lytic peptide Phor21-FSHβ conjugate.Molecular medicine (Cambridge, Mass.) · 2025Article
- The role of recombinant LH in ovarian stimulation: what's new?Reproductive biology and endocrinology : RB&E · 2025Review
- Article
- Revisiting the follicle-stimulation hormone receptor expression and function in human myometrium and adipose tissue.Molecular medicine (Cambridge, Mass.) · 2024Article
- Effects of follicle-stimulating hormone on energy balance and tissue metabolic health after loss of ovarian function.American journal of physiology. Endocrinology and metabolism · 2024Article
- Extra-Gonadal and Non-Canonical Effects of FSH in Males.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Article
- Inadequate detection of the FSHR complicates future research on extragonadal FSHR localization.Frontiers in endocrinology · 2023Article
- Effects of Chinese herbal feed additives on the sperm quality and reproductive capacity in breeding boars.Frontiers in veterinary science · 2023Article
- Article
- Follicle-Stimulating Hormone Promotes the Development of Endometrial CancerInternational journal of environmental research and public health · 2022Article
- Expression and function of the luteinizing hormone choriogonadotropin receptor in human endometrial stromal cells.Scientific reports · 2022Article
- Effect of human follicle-stimulating hormone on immunomodulatory function of decidual mesenchymal stem cells by reducing interleukin-6 levels.Journal of ovarian research · 2022Article
- Human pluripotent stem cell-derived cells endogenously expressing follicle-stimulating hormone receptors: modeling the function of an inactivating receptor mutation.Molecular human reproduction · 2022Article
- Regulation of antral follicular growth by an interplay between gonadotropins and their receptors.Journal of assisted reproduction and genetics · 2022Review
- Overview of follicle stimulating hormone and its receptors in reproduction and in stem cells and cancer stem cells.International journal of biological sciences · 2022Review
- The Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens.Endocrine reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expression of the follicle-stimulating hormone receptor (FSHR), besides gonadal tissues, has recently been detected in several extragonadal normal and tumorous tissues, including different types of primary and metastatic cancer and tumor vessel endothelial cells (TVEC). The suggested FSH actions in extragonadal tissues include promotion of angiogenesis, myometrial contractility, skeletal integrity, and adipose tissue accumulation. Non-malignant cells within cancer tissue have been shown to be devoid of FSHR expression, which implies a potential role of FSHR as a diagnostic, prognostic, or even a therapeutic tool. There are shared issues between several of the published reports questioning the validity of some of the conclusion. Firstly, protein expression of FSHR was performed solely with immunohistochemistry (IHC) using either an unavailable "in house" FSHR323 monoclonal antibody or poorly validated polyclonal antibodies, usually without additional methodological quality control and confirmations. Secondly, there is discrepancy between the hardly traceable or absent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.